Novartis AG
NVS · NYSE
9/29/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $239,016,600 | $235,727,480 | $219,392,640 | $193,354,970 |
| - Cash | $9,556,000 | $6,656,000 | $7,066,000 | $11,459,000 |
| + Debt | $32,022,000 | $32,637,000 | $31,270,000 | $31,258,000 |
| Enterprise Value | $261,482,600 | $261,708,480 | $243,596,640 | $213,153,970 |
| Revenue | $14,358,000 | $14,836,000 | $13,620,000 | $13,558,000 |
| % Growth | -3.2% | 8.9% | 0.5% | – |
| Gross Profit | $10,819,000 | $11,514,000 | $10,393,000 | $10,234,000 |
| % Margin | 75.4% | 77.6% | 76.3% | 75.5% |
| EBITDA | $5,841,000 | $6,076,000 | $5,831,000 | $5,188,000 |
| % Margin | 40.7% | 41% | 42.8% | 38.3% |
| Net Income | $3,928,000 | $4,041,000 | $3,606,000 | $2,818,000 |
| % Margin | 27.4% | 27.2% | 26.5% | 20.8% |
| EPS Diluted | 0.62 | 2.06 | 1.82 | 1.41 |
| % Growth | -69.9% | 13.2% | 29.1% | – |
| Operating Cash Flow | $6,571,000 | $6,664,000 | $3,645,000 | $4,193,000 |
| Capital Expenditures | -$831,000 | -$558,000 | -$1,494,000 | -$1,131,000 |
| Free Cash Flow | $5,740,000 | $6,106,000 | $2,151,000 | $3,062,000 |